About Maravai LifeSciences Holdings,
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Maravai LifeSciences Holdings, (MRVI) is a Healthcare company in the Biotechnology industry with a market capitalisation of $2.6B.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.6B
- Forward P/E
- -66.31
- EPS (TTM)
- $-0.53
- Revenue (TTM)
- $208.8M
- Free cash flow
- -$3.6M
- Profit margin
- -37.1%
- Beta
- 0.60
- Shares outstanding
- 149M
Financial health: Weak2.8/10
1 strength, 5 concerns. Weakest points: debt to equity, net debt vs cash flow, return on equity and 2 more.
- Debt to equity: 1.37 (Concern, benchmark < 0.5) — Debt of 1.37x equity is high against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: — (Concern, benchmark < 4 years) — Carries $74.9M of net debt while free cash flow is negative, so the debt is not being repaid from the business.
- Current ratio: 6.60 (Strong, benchmark > 1.5) — Short-term assets cover 6.60x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
- Return on equity: -33.1% (Concern, benchmark > 15%) — Earns -33.1% on shareholder equity, well short of the > 15% mark.
- Gross margin: 35.7% (Watch, benchmark > 40%) — Keeps 35.7% of revenue after the direct cost of sales, short of the > 40% mark.
- Net margin: -37.1% (Concern, benchmark > 10%) — Turns -37.1% of revenue into profit, well short of the > 10% mark.
- Free cash flow: -$70.7M (Concern, benchmark positive) — Burned $70.7M of cash after capital spending, so operations did not fund themselves. It has deteriorated over the last 4 years.
- Revenue growth: 8.5% (Watch, benchmark > 10%) — Revenue changed 8.5% year on year, short of the > 10% mark.
- Earnings growth: 9.7% (Watch, benchmark > 10%) — Earnings changed 9.7% year on year, short of the > 10% mark.